Proof of concept (POC) animal study highlighting conduits treated with ADAPT® tissue technology demonstrated no
calcification evident. This was a milestone and a major step towards ADAPT® treated prosthetic conduits being utilised in
CABG (coronary artery bypass graft) surgeries.
800,000 surgeries using CABG per year
$16b market
Ann: Preliminary Final Report, page-6
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.75 |
Change
-0.230(1.21%) |
Mkt cap ! $360.4M | |||
| Open | High | Low | Value | Volume |
| $19.00 | $19.00 | $18.52 | $179.2K | 9.566K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 109 | $18.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.75 | 999 | 1 |
View Market Depth
| Last trade - 16.10pm 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$18.52 |
Change
-0.230 ( 2.01 %) |
||||
| Open | High | Low | Volume | ||
| $18.52 | $18.52 | $18.52 | 14 | ||
| Last updated 10.49am 30/05/2024 ? | |||||
| AVR (ASX) Chart |